ClinicalTrials.gov

History of Changes for Study: NCT03860155
Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
Latest version (submitted November 9, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 28, 2019 None (earliest Version on record)
2 March 20, 2019 Recruitment Status, Study Status and Contacts/Locations
3 December 12, 2019 Contacts/Locations, Study Status, Eligibility, Outcome Measures, Arms and Interventions, Study Description and Oversight
4 August 26, 2021 Recruitment Status, Contacts/Locations and Study Status
5 November 9, 2021 Recruitment Status, Study Status and Study Design
Comparison Format:

Scroll up to access the controls

Study NCT03860155
Submitted Date:  February 28, 2019 (v1)

Open or close this module Study Identification
Unique Protocol ID: allo-APZ2-ACLF-II-01
Brief Title: Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
Official Title: An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF)
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2019
Overall Status: Not yet recruiting
Study Start: March 2019
Primary Completion: February 2020 [Anticipated]
Study Completion: October 2021 [Anticipated]
First Submitted: January 31, 2019
First Submitted that
Met QC Criteria:
February 28, 2019
First Posted: March 1, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
February 28, 2019
Last Update Posted: March 1, 2019 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: RHEACELL GmbH & Co. KG
Responsible Party: Sponsor
Collaborators: FGK Clinical Research GmbH
Ticeba GmbH
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v. doses of the investigational medicinal product (IMP) allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF). The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.
Detailed Description:

This is an interventional, phase I/IIa clinical trial to investigate the efficacy (by changes in Model for End-Stage Liver Disease [MELD] score) and safety (by monitoring adverse events) of the IMP in patients with acute-on-chronic liver failure grade 2 and 3. The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

The clinical trial will be conducted in Germany and will consist of a screening, treatment and efficacy follow-up period, and a safety follow-up period.The total duration is planned to be about 3 years including the follow-up period.

The planned sample size is up to 18 treated patients. 2 x 10e6 cells/kg, each at Day 0, Day 4 and Day 11, will be administrated into peripheral vein (arm) by use of a perfusor. allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in HRG-solution. In patients which require dialysis, the IMP application has to be performed at least 3 hours after end of dialysis. This is necessary to ensure that cells and secreted molecules are not cleared from the system by the dialysis.

Patients will be followed up for 24 weeks with clinic visits at Weeks 3, 4, 8, 12, 16, 20 and 24 after IMP application. Further safety follow-ups will be scheduled as home interviews via telephone at Months 15 and 24. If necessary (at the discretion of the investigator), safety follow-ups at Months 15 and 24 can also be carried out as an on-site visit.

The first six patients will be enroled into the clinical trial consecutively with an interval of 2 weeks between the third IMP-application of the first patient and the enrolment of the second patient, etc. During this period the patient receives all three applications and immediate severe adverse effects (allergic reactions, SIRS) that could occur after treatment would be reported before treatment start of the next patient.

The safety data of these first six patients will be reviewed by the Medical Monitor continuously, if required with assistance of the Coordinating Investigator and the sponsor's Medical Officer. A safety evaluation will be submitted to the competent authority and recruitment can only be continued after approval of an amendment.

Open or close this module Conditions
Conditions: Acute-On-Chronic Liver Failure
Keywords: Acute-on-Chronic Liver Failure
ACLF
ABCB5
ATP Binding Cassette Subfamily B Member 5
allogeneic
mesenchymal stem cells
advanced therapy medicinal product
somatic cell therapy
phase I/IIa
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1/Phase 2
Interventional Study Model: Single Group Assignment
Number of Arms: 1
Masking: None (Open Label)
Allocation: N/A
Enrollment: 18 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: allo-APZ2-ACLF
Application of IMP into peripheral vein (arm) by use of a perfusor.
Biological: allo-APZ2-ACLF

Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 4 and Day 11 into peripheral vein (arm) by use of a perfusor.

allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.

Other Names:
  • Skin-derived ABCB5-positive mesenchymal stem cells
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change of Model for End-Stage Liver Disease (MELD) score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.
[ Time Frame: Week 24, or last available post-baseline measurement of Days 4 or 11 or Weeks 3, 4, 8, 12, 16 or 20 if the Week 24 measurement is missing [LOCF]. ]

Model for End-Stage Liver Disease (MELD) score for assessing the severity of chronic liver disease is measured as absolute change to baseline score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.
2. Assessment of adverse event (AE) occurrence
[ Time Frame: Between Screening and Month 24 ]

All AEs occurring during the clinical trial will be registered, documented and evaluated.
Secondary Outcome Measures:
1. Change of MELD score at Weeks 3, 4, 8, 12, 16 and 20
[ Time Frame: Weeks 3, 4, 8, 12, 16 and 20 ]

Model for End-Stage Liver Disease score is measured as absolute change to baseline score.
2. Change of Child-Pugh-Score at Weeks 3, 4, 8, 12, 16, 20 and 24
[ Time Frame: Weeks 3, 4, 8, 12, 16, 20 and 24 ]

Child-Pugh-Score to assess the prognosis of chronic liver disease and cirrhosis is measured as absolute change to baseline score.
3. Change of CLIF-C ACLF score at Weeks 3, 4, 8, 12, 16, 20 and 24
[ Time Frame: Weeks 3, 4, 8, 12, 16, 20 and 24 ]

CLIF-C ACLF score to assess the mortality in Acute-on-chronic liver failure patients is measured as absolute change to baseline score.
4. Overall survival time until Week 24
[ Time Frame: Between Screening and Week 24 ]

Assessment of overall survival time.
5. Complications of ACLF (hepatorenal syndrome [HRS], variceal bleeding, ascites, hepatic encephalopathy [HE], spontaneous bacterial peritonitis [SBP])
[ Time Frame: Between Screening and Week 24 ]

Assessment, documentation and evaluattion of ACLF related complications (hepatorenal syndrome, variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis).
6. Transient elastography assessment at Weeks 4, 12 and 24
[ Time Frame: Weeks 4, 12 and 24 ]

Mapping of the elastic properties and the stiffness of the tissue as assessed by transient elastography imaging
7. Infections (proven infection necessitating systemic use of antibiotics)
[ Time Frame: Between Screening and Month 24 ]

All infections occurring during the clinical trial will be registered, documented and evaluated.
8. Change of levels of C-reactive protein in serum at Weeks 3, 4, 8, 12, 16, 20 and 24
[ Time Frame: Weeks 3, 4, 8, 12, 16, 20 and 24 ]

C-reactive protein levels in the serum will be measured.
9. Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24
[ Time Frame: Weeks 3, 4, 8, 12, 16, 20 and 24 ]

The following laboratory variables will be measured and evaluated:

Albumin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).

10. Changes in the profile of 80 different immunomodulatory cytokines at Weeks 3, 4, 8, 12, 16, 20 and 24
[ Time Frame: Weeks 3, 4, 8, 12, 16, 20 and 24 ]

Fluorescence based analysis of 80 different immunomodulatory cytokine parameters in the patient's serum samples as assessed by a 80plex Human Cytokine Antibody Array Kit.
11. Changes in dialytic treatment until Week 24
[ Time Frame: Between Screening and Week 24 ]

For patients with dialysis prior to Screening: Time to first dialysis after first IMP administration and time to last dialysis after first IMP administration until Week 24 will be assessed.

For patients with no dialytic treatment prior to Screening the overall diaylsis timespan from first dialysis after first IMP administration until last dialysis will be measured.

12. Time to respiratory failure after first IMP administration until Week 24
[ Time Frame: Between Day 0 (after first IMP administration) and Week 24 ]

Timespan to respiratory failure after first IMP administration until Week 24 will be measured.
13. Duration of the initial hospital stay
[ Time Frame: Between Screening and Week 24 ]

Initial hospitalisation time will be evaluated.
14. Duration of initial intensive care stay
[ Time Frame: Between Screening and Week 24 ]

The duration of initial intensive care stay will be evaluated.
15. Optional: Evaluation of liver biopsy (necrosis quantification)
[ Time Frame: Between Week 8 and Week 24 ]

Extent of necrosis will be quantified by the pathologist of the clinical trial center.
16. Physical examination at Week 24
[ Time Frame: Week 24 ]

A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.
17. Vital signs at Week 24: Body temperature
[ Time Frame: Week 24 ]

Body temperature will be measured.
18. Vital signs at Week 24: Blood pressure
[ Time Frame: Week 24 ]

Blood pressure will be measured.
19. Vital signs at Week 24: Heart rate
[ Time Frame: Week 24 ]

Heart rate will be measured.
20. Vital signs at Week 24: Respiratory rate
[ Time Frame: Week 24 ]

Respiratory rate will be measured.
21. Hematological laboratory parameters at Week 24
[ Time Frame: Week 24 ]

The hematological laboratory values for "hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, platelet count" will be measured.
22. Clinical chemistry parameters at Week 24
[ Time Frame: Week 24 ]

The clinical chemistry values for "sodium, potassium, calcium, urea, creatinine, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, CRP" will be measured.
23. Coagulation parameter "factor V" at Week 24
[ Time Frame: Week 24 ]

The coagulation value for "factor V" will be measured.
24. Coagulation parameter "INR" at Week 24
[ Time Frame: Week 24 ]

The coagulation value for "INR" will be measured.
25. Overall survival at Week 24 and at Month 24
[ Time Frame: Week 24, Month 24 ]

Overall survival at Week 24 and at Month 24 will be evaluated.
Open or close this module Eligibility
Minimum Age: 20 Years
Maximum Age: 75 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Male or female patients, aged 20 to 75 years;
  2. Diagnosed ACLF of grade 2 or 3 according to EASL-CLIF definition;
  3. Patients are not eligible for liver transplant (confirmed by transplantation board);
  4. Histology result of liver biopsy not older than 4 weeks before screening;
  5. Women of childbearing potential must have a negative blood pregnancy test at screening;
  6. Women of childbearing potential and fertile man, and their partners must be willing to use highly effective contraceptive methods during the course of the clinical trial;
  7. Written informed consent from patient, legal or authorized representative or a confirmation of justification of trial participation by an independent medical consultant. In case of confirmation by the independent medical consultant, a deferred informed consent from patient, legal or authorized representative has to be given.

Exclusion Criteria:

  1. Patients without cirrhosis;
  2. Patients with ACLF grade 1 according to EASL-CLIF definition;
  3. Patient with septic shock;
  4. Patients with known hepatopulmonal syndrome (HPS);
  5. Patients with known pulmonary embolism that needs anticoagulative treatment;
  6. Patients with pre-existing lung disease with necessity of respiratory support;
  7. Active malignancy or history of malignancy within 5 years prior to trial entry;
  8. Known infection with human immunodeficiency virus (HIV˗1, HIV-2);
  9. Any known allergies to components of the IMP;
  10. Current or previous (within 30 days of enrolment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
  11. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
  12. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
  13. Pregnant or nursing women;
  14. Employees of the sponsor, or employees or relatives of the investigator.
Open or close this module Contacts/Locations
Central Contact Person: Christoph Ganss, Dr. med.
Telephone: +49 6221 71833 Ext. 0
Email: office@rheacell.com
Central Contact Backup: Kathrin Dieter
Telephone: +49 6221 71833 Ext. 0
Email: kathrin.dieter@rheacell.com
Study Officials: Matthias Ebert, Prof. Dr.
Principal Investigator
Med. Fakultät Mannheim der Universität Heidelberg, II. Med. Klinik, Germany
Locations: Germany
Universitätsklinikum Carl-Gustav-Carus an der TU Dresden, Medizinische Klinik I
Dresden, Germany, 01307
Contact:Contact: Marco Berning, Dr. med.
Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie, Medizinisches Forschungszentrum
Essen, Germany, 45147
Contact:Contact: Christian Lange, Prof. Dr.
Universitätsklinikum Magdeburg A.ö.R., Medizinische Fakultät der Otto-von-Guericke-Universität
Magdeburg, Germany, 39120
Contact:Contact: Ali Canbay, Prof. Dr.
Medizinische Fakultät Mannheim der Universität Heidelberg, II. Medizinische Klinik
Mannheim, Germany, 68167
Contact:Contact: Matthias Ebert, Prof. Dr.
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services